Fig. 1: SOAT1 predicts a poor prognosis, and its inhibitor avasimibe sensitizes glioma to Erastin in vivo. | Cell Death & Disease

Fig. 1: SOAT1 predicts a poor prognosis, and its inhibitor avasimibe sensitizes glioma to Erastin in vivo.

From: Ferroptosis sensitization in glioma: exploring the regulatory mechanism of SOAT1 and its therapeutic implications

Fig. 1

A Human glioma tissue was stained with HE (above), oil red (below). Scale bar = 50 μm. B Total cholesterol and cholesterol ester content in glioma tissues were measured. C SOAT1 protein expression and location in human glioma tissues was marked by immunofluorescence. Scale bar = 50 μm. D Western blot analysis of SOAT1 protein in normal brains and paired glioma tissues. E Analysis of SOAT1 expression in normal brains and glioma tissues based on TCGA database data, and analysis of SOAT1 expression in glioma tissues of different grades in CGGA database. F The overall survival and progress free survival curve of SOAT1 expression between high and low grade gliomas was analyzed based on TCGA database data. G–I The luciferase activity of intracranial tumor, body weight and survival time of mice showed that avasimibe enhanced the effectiveness of erastin. Data significance is denoted as follows: *p < 0.05; **p < 0.01.

Back to article page